Y. Nan

Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.

J. English, P. Kirschmeier, W. Windsor, 2014, Journal of medicinal chemistry.

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

K. Cox, P. Kirschmeier, R. Doll, 2018, ACS medicinal chemistry letters.

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.

P. Kirschmeier, R. Doll, W. Windsor, 2018, Bioorganic & medicinal chemistry letters.